中国临床心理学杂志

非典型抗精神病药对首发精神分裂症患者记忆功能的影响

作者：杨绪娜¹ 2 朱峰¹ 2 李乐华²

单位：1. 苏州市广济医院江苏苏州215008
2. 中南大学湘雅二医院湖南长沙410011

分类号：R749.3

出版年,卷(期):页码：2011,19(1):59-62

摘要：

目的：探讨奥氮平、利培酮和阿立哌唑三种非典型抗精神病药对首发精神分裂症患者认知功能的影响。91例首发精神分裂症患者通过多中心随机分配，奥氮平组(n=27)、利培酮组(n=37)和阿立哌唑组(n=27)，在治疗前和12周后完成如下测评：阳性与阴性症状量表(Positive and Negative Syndrome Scale，PANSS)、韦氏记忆量表-第三版(Wechsler Memory Scale，WMS-Ⅲ)的空间广度测验、霍普金斯词汇学习测验-修订版(Hopkins Verbal Learning Test-Revised，HVLT-R)。结果：①治疗12周后，三组PANSS评分均较治疗前显著降低(P<0.001)，三组间PANSS减分率的差异无统计学显著性。②空间广度方面，阿立哌唑组治疗后的顺行得分和总分(8.48±2.26，15.59±3.61)较治疗前(7.52±1.72，14.11±3.63)显著增加(P<0.05)，奥氮平组和利培酮组前后比较差异均无统计学显著性(P>0.05)。③HVLT-R得分方面，奥氮平组和利培酮组治疗后即刻回忆数、回忆总数和再认得分较治疗前显著增加(P<0.05～0.01)，阿立哌唑组治疗后HVLT-R的所有得分均较治疗前显著增加(P<0.05～0.01)，三组患者即刻回忆数、回忆总数和再认的改善值比较差异均无统计学显著性(P>0.05)。阿立哌唑对首发精神分裂症患者记忆功能的改善在一定程度上优于奥氮平和利培酮。

Objective:explore the efficacy of olanzapine,risperidone and aripiprazole on memory function in patientswith first-episode schizophrenia.Methods:91 first-episode patients with schizophrenia were randomized to olanzapinegroup (n=27),risperidone group (n=37) and aripiprazole group (n=27).All subjects were assessed with Positive andNegative Syndrome Scale(PANSS),Hopkins Verbal Learning Test-Revised(HVLT-R),Wechsler Memory Scale-Ⅲ(WMS-Ⅲ) and Spatial Span Task.Results:①Compared with the baseline,all the scores of PANSS decreased significantly (P ＜0.001),but no significant difference was found among the three groups (P＞0.05).②Compared with the baseline,the totalscore and the Anterograde score of Spatial Span Test increased significantly (P<0.05) in aripiprazole group,but no significantchanges were found in olanzapine group and risperidone group (P>0.05).③Compared with the baseline,the scores ofimmediate recall,total recall and recognition about HVLT-R increased significantly(P<0.05~0.01) in olanzapine group andrisperidone group,and all the scores of HVLT-R increased significantly(P<0.05~0.01) in aripiprazole group,but no significantdifference was found among the three groups (P ＞0.05).Conclusion:The improvement in memory function of aripiprazolewould be probably better than olanzapine and risperidone.

基金项目：

“十一五”国家科技支撑课题“精神分裂症早期诊断技术与规范化治疗研究”

作者简介：

参考文献：

[1] .Medalia A,Lim R.Treatment of cognitive Dysfunction inPsychiatric Disorders.Journal of Psychiatric Practice,2004,10(1):17-25
[2] .Bilder RM,Goldman RS,Robinson D,et al.Neuropsychologyof first-episode schizophrenia:Initial characterizationand clinical correlates.Am J Psychiatry,2000,57:549-559
[3] .Green MF.What are the functional consequences of neurocognitivedeficits in schizophrenia? Am J Psychiatry,1996,153:321-330
[4] .Keefe RS,Sweeney JA,Hongbin GU,et al.Effect of olanzapine,quetiapine and risperidone on neurocognitive functionin early psychosis:A randomized,double-blind 522-weekcomparison.Am J Psychiatry,2007,164:1061-1071
[5] .Harvey PD.Cognitive effects of risperidone and olanzapinein patients with schizophrenia or schizoaffective disorder,in2000 Annual Meeting New Research Program and Abstracts.Washington DC.American Psychiatric Association,2000.149
[6] .Harvey PD,Keefe RS.Studies of cognitive change in patientswith schizophrenia following novel antipsychotic treatment.Am J Psychiatry,2001,158:176-184
[7] .Woodward ND,Purdon SE,Meltzer HY,et al.A meta-analysisof neuropsychological change to clozapine,olanzapine,quetiapine and risperidone in schizophrenia.Int J Neuropsychopharmacol,2005,8:457-472
[8] .Kay SR,Fiszbein A,Opler LA.The positive and negativesyndrome scale(PANSS) for schizophrenia.Schizophr Bull,1987,13:261-276
[9] .阳性和阴性症状量表中文版.西安杨森制药有限公司印刷,1-68
[10] .石川,于欣,吴尊友,等.中国HIV + / AIDS 患者神经心理学初步研究.中国心理卫生杂志,2005,19:343-346
[11] .Silver H,Feldman P,Bilker W,et al.Working MemoryDeficit as a Core Neuropsycholo-gical Dysfunction inschizophrenia.Am J Psychiatry,2003,160:1809-1816
[12] .Wolf RC,Vasic N,Walter H.The concept of working memoryin schizophrenia:current evidence and future perspectives.Fortschr Neurol Psychiatr.2006,74(8):449-468
[13] .Brewer,Francy SM,Wood SJ,et al.Memory impairmentsidentified in people at ultra-high risk for psychosis who laterdevelop first-episode psychosis.Am J Psychiatry,2005,162:71-78
[14] .Shapiro DA,Renock S,et al.Aripiprazole,a novel atypicalantipsychotic drug with a unique and robust pharmacology.Neuropsychopharmacology,2003,28(8):1400-1411
[15] .Volavka J,Czobor P,Sheitman B,et al.Clozapine,olanzapine,risperidone and haloperidol in the treatment of patientswith schizophrenia and schizoaffective disorder.Am J Psychatry,2002,159:255-262
[16] .Franz M,Lis S,Pluddem K,et al.Conventional versusatypical neuroleptics:subjective quality of life in schizophrenicpatients.BR J Psychiatry,1997,l70:422-425
[17] .Kern RS,Green MF,Cornblatt BA,et al.The neurocognitiveeffects of aripiprazole:An open-label comparison witholanzapine.Psychopharmacology,2006,187(3):312-320
[18] .Bilder RM,Goldman RS,Volavka J,et a1.Neurocogn itiveeffects of clozapine olanzapine,risperidone and halopefidolin patients with chronic schizophrenia or Schizo affectivedisorder.Am J Psychiatry,2002,159(12):2118-2119
[19] .吴仁荣,李乐华.新型抗精神病药物:阿立哌唑.国外医学精神病分册,2004,31(3):177-179
[20] .Burris KD,Molski TF,Xu C,et al.Aripiprazole,a novelantipsychotic,is a high affinity partial agonist at humandopine D2.receptors.Pharmacol Exp Ther,2002,302.(1):381-389
[21] .Jordan S,Koprivica V,Chen R,et al.The antipsychoticaripiprazole is a potent,partial agonist at the human 5-HT1Areceptor.Eur J Pharmacol,2002,441(3):137-140

服务与反馈：

【文章下载】【加入收藏】